Top biopharmaceutical companies in cardiometabolic revenue 2020

In 2020, the highest total revenue made by a biopharmaceutical companies specialized in cardiometabolic care worldwide was around 28 billion U.S. dollars by Eli Lilly. This statistic illustrates the total revenue of leading biopharmaceutical companies in cardiometabolic worldwide.

Total revenue of leading biopharmaceutical companies in cardiometabolic care worldwide in 2020* (in billion U.S. dollars)

Characteristic	Total revenue in billion U.S. dollars
Eli Lilly	28
Boehringer Ingelheim	23
Novo Nordisk	21
Servier	5.5
Menarini	4.7
Kowa Pharma	1.8
Recordati	1.8
Italfarmaco	0.8
Grupo Ferrer	0.7
Amarin	0.6

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

November 2021

More information

Region

Worldwide

Survey time period

2020

Supplementary notes

* The table lists the most valuable branded players whose leading product(s) are in the cardiometabolic field.
Major players in diabetes care that are not listed here due to the strength of other franchise areas include Merck and Sanofi.
Beyond diabetes care, core drivers in the cardiometabolic disease area were legacy sales from statins/blood pressure medications and novel anticoagulants led by Bayer with Xarelto.

Citation formats